Episode 19: A Between the Biotech Waves Conversation with JeanFrancois Formela, Partner at Atlas Venture & multi-biotech company founder
Between the Biotech Waves
00:00
How Did You Think About Permanently Modifying Human DNA?
The first application of TTR is essentially cutting, right? So we're inducing loss of function. And the answer to the dilemma was that we were hoping that it would be highly targeted. But when you're looking at therapeutic targets that are very constrained in terms of algae and exactly what you're doing and what you're not doing, I didn't feel that it was an overwhelming challenge.
Transcript
Play full episode
